Xenetic Biosciences, Inc. (XBIO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 589,897 | 593,261 | 614,243 | 726,404 |
| Research and development | 656,557 | 879,029 | 367,985 | 933,771 |
| General and administrative | 657,752 | 656,641 | 745,731 | 1,130,029 |
| Total operating costs and expenses | 1,314,309 | 1,535,670 | 1,113,716 | 2,063,800 |
| Loss from operations | -724,412 | -942,409 | -499,473 | -1,337,396 |
| Other income (expense) | 1,477 | 78 | 1,504 | -21 |
| Interest income, net | 34,232 | 39,190 | 61,298 | 63,447 |
| Total other income | 35,709 | 39,268 | 62,802 | 63,426 |
| Net loss | -688,703 | -903,141 | -436,671 | -1,273,970 |
| Basic net loss per share | -0.45 | -0.59 | -0.28 | -0.83 |
| Diluted net loss per share | -0.45 | -0.59 | -0.28 | -0.83 |
| Weighted-average shares of common stock outstanding, basic | 1,542,139 | 1,542,139 | 1,541,722 | 1,540,799 |
| Weighted-average shares of common stock outstanding, diluted | 1,542,139 | 1,542,139 | 1,541,722 | 1,540,799 |